FierceBiotechOriginal article
{"a":[{"_":"Crystalys mines $130M series B to push gout drug through phase 3","$":{"href":"/biotech/crystalys-mines-130m-series-b-round-de-risked-gout-therapy","hreflang":"en"}}]}
dotinuradPositive
AI Analysis
Summary
Crystalys Therapeutics raised $130 million in Series B financing to advance gout drug dotinurad through Phase 3 and prepare for commercial launch.
Clinical Trial Data
Phase
Phase 3
Importance:6/10
Sentiment:
0.60
financingseries Bgoutphase 3capital raise
Read the original article
Published by FierceBiotech on July 21, 2026 2:03 PM